569 related articles for article (PubMed ID: 33356518)
21. Increased Mortality with Repeat Lumpectomy Alone After Ipsilateral Breast Tumor Recurrence.
Su Y; Guo R; Xue J; Chi Y; Chi W; Wang J; Yang B; Wu J
Oncologist; 2019 Sep; 24(9):e818-e827. PubMed ID: 30842240
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer is not a contraindication for breast conservation.
Adkins FC; Gonzalez-Angulo AM; Lei X; Hernandez-Aya LF; Mittendorf EA; Litton JK; Wagner J; Hunt KK; Woodward WA; Meric-Bernstam F
Ann Surg Oncol; 2011 Oct; 18(11):3164-73. PubMed ID: 21947595
[TBL] [Abstract][Full Text] [Related]
23. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
25. [The influence of molecular classification of breast cancer on the safety of breast-conserving surgery].
Li Y; Mu L; Ruan YX; Wang YT; Zhang D; Zhou H; Wang X
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):341-346. PubMed ID: 29860760
[No Abstract] [Full Text] [Related]
26. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients.
Wang SE; Sun YD; Zhao SJ; Wei F; Yang G
Math Biosci Eng; 2019 Sep; 17(1):92-104. PubMed ID: 31731341
[No Abstract] [Full Text] [Related]
27. HER2-Overexpressing Ductal Carcinoma
O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
[TBL] [Abstract][Full Text] [Related]
28. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
29. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
31. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis.
Chen J; Jiang P; Wang HJ; Zhang JY; Xu Y; Guo MH; Zhang B; Tang CY; Cao HY; Wang S
World J Surg Oncol; 2014 Jul; 12():212. PubMed ID: 25022995
[TBL] [Abstract][Full Text] [Related]
33. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of Surgical Treatment After Ipsilateral Breast Tumor Recurrence.
Wu Y; Shi X; Li J; Wu G
J Surg Res; 2021 Feb; 258():23-37. PubMed ID: 32980773
[TBL] [Abstract][Full Text] [Related]
36. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
Ogiya R; Sagara Y; Niikura N; Freedman RA
Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
[TBL] [Abstract][Full Text] [Related]
37. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
38. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
Wong SM; Freedman RA; Sagara Y; Aydogan F; Barry WT; Golshan M
Ann Surg; 2017 Mar; 265(3):581-589. PubMed ID: 28169929
[TBL] [Abstract][Full Text] [Related]
39. Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.
Wu W; Cheng S; Deng H; Wu J; Mao K; Cao M
Medicine (Baltimore); 2016 Jan; 95(3):e2547. PubMed ID: 26817902
[TBL] [Abstract][Full Text] [Related]
40. Breast-conserving Surgery Rates in Breast Cancer Patients With Different Molecular Subtypes: An Observational Study Based on Surveillance, Epidemiology, and End Results (SEER) Database.
Chen K; Li S; Li Q; Zhu L; Liu Y; Song E; Su F
Medicine (Baltimore); 2016 Feb; 95(8):e2593. PubMed ID: 26937898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
